Int Ophthalmol (2018) 38:1357–1362 https://doi.org/10.1007/s10792-017-0592-5 CASE REPORT Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy . . . Laura R. Steeples Paul Spry Richard W. J. Lee Ester Carren ˜ o Received: 7 January 2017 / Accepted: 5 June 2017 / Published online: 12 June 2017 Springer Science+Business Media B.V. 2017 Abstract 256.2 ± 39.7 lm at 6 months and 235.5 ± 32.5 lmat Purpose To report the clinical outcomes of adali- 12 months. Adalimumab permitted cessation or reduction mumab therapy in cases of birdshot chorioretinitis in the daily dose of oral prednisolone plus withdrawal of a (BCR) with cystoid macular edema (CME) refractory second-line agent in all patients. to conventional immunotherapy. Conclusions In these patients, adalimumab was Methods This is a retrospective case series of three effective in the treatment of refractory CME. BCR patients treated with adalimumab for refractory CME. The main outcome measure was central subﬁeld Keywords Birdshot chorioretinopathy Birdshot thickness (CST) on optical coherence tomography. chorioretinitis Adalimumab Anti-tumor necrosis Any patients treated with local steroids and/or receiv- factor alpha (anti-TNF) Cystoid macular edema ing systemic steroids higher than 40 mg prednisolone daily during adalimumab therapy were excluded. Introduction Results
International Ophthalmology – Springer Journals
Published: Jun 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera